惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

WordPress大学
WordPress大学
G
Google Developers Blog
小众软件
小众软件
V
V2EX
月光博客
月光博客
腾讯CDC
aimingoo的专栏
aimingoo的专栏
J
Java Code Geeks
Y
Y Combinator Blog
人人都是产品经理
人人都是产品经理
B
Blog RSS Feed
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
Microsoft Azure Blog
Microsoft Azure Blog
博客园 - 【当耐特】
D
Docker
M
MIT News - Artificial intelligence
Google DeepMind News
Google DeepMind News
N
Netflix TechBlog - Medium
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
I
InfoQ
MongoDB | Blog
MongoDB | Blog
Apple Machine Learning Research
Apple Machine Learning Research
Jina AI
Jina AI

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
2026-05-14 · via All Articles on Seeking Alpha

Q1: 2026-05-07 Earnings Summary

EPS of $0.13 misses by $0.06

 | 

Revenue of

$893.65M

(25.52% Y/Y)

beats by $3.01M

Genmab A/S (GMAB) Q1 2026 Earnings Call May 7, 2026 12:00 PM EDT

Company Participants

Jan van de Winkel - Co-Founder, President & CEO
Brad Bailey - Executive VP & Chief Commercial Officer
Anthony Pagano - Executive VP & CFO
Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimental Medicines
Judith Klimovsky - Executive VP & Chief Development Officer

Conference Call Participants

Jonathan Chang - Leerink Partners LLC, Research Division
Zain Ebrahim - JPMorgan Chase & Co, Research Division
James Gordon - Barclays Bank PLC, Research Division
Xian Deng - UBS Investment Bank, Research Division
Rajan Sharma - Goldman Sachs Group, Inc., Research Division
Michael Schmidt - Guggenheim Securities, LLC, Research Division
Benjamin Jackson - Jefferies LLC, Research Division
Charlie Haywood - BofA Securities, Research Division
Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division
Matthew Phipps - William Blair & Company L.L.C., Research Division
Yaron Werber - TD Cowen, Research Division
Romy O'Connor - Van Lanschot Kempen NV
Victor Floch - BNP Paribas, Research Division
Kalpit Patel - Wolfe Research, LLC
Judah Frommer - Morgan Stanley, Research Division

Presentation

Operator

Hello, and welcome to the Genmab First Quarter 2026 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects.

Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as a part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.